Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
Pipeline and key clinical candidates for these companies:
Exicure is an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company says it continues to actively pursue out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain, and to pursue all strategic alternatives with the goal of maximizing stockholder value.
Syros says it is "committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies, driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches." Syros is developing tamibarotene, an oral selective RARalpha agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression.
BioNTech is "pioneering novel therapies for cancer and other serious diseases." BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab (GMAB), Sanofi (SNY), Genentech, a member of the Roche Group (RHHBY), Regeneron (REGN), Genevant, Fosun Pharma, and Pfizer (PFE).
Arcturus Therapeutics is a late-stage clinical mRNA medicines and vaccines company whose pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for COVID-19 and Influenza, and other programs to potentially treat ornithine transcarbamylase, or OTC, deficiency, and cystic fibrosis, or CF. The company's partnered programs include glycogen storage disease type III and hepatitis B virus.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart believes that its proprietary pill vaccine delivery platform is "suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications," the company has stated. Vaxart's development programs currently include pill vaccines designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus, or RSV, as well as a therapeutic vaccine for human papillomavirus, or HPV, Vaxart's first immune-oncology indication.
Recent news on these stocks:
September 16
JPMorgan upgraded BioNTech to Neutral from Underweight with a price target of $125, up from $91. The company presented multiple updates on its oncology pipeline and JPMorgan is "particularly impressed" by some of the Phase II and Phase I/II data that has been coming out for BNT327/PM8002, the anti-VEGF-A/PD-L1 bispecific, the analyst tells investors in a research note. The firm sees BioNTech as a company that needs to diversify beyond COVID, and its cautious view on the stock had centered on the lack of sufficient randomized data from the oncology pipeline to instill confidence in that transition and shift the narrative. It now thinks BNT327 "could be a fly-wheel product" that potentially provides BioNTech "with not only a string of interesting clinical updates in the near-term, but also meaningful diversification away from the COVID vaccine business in the second half of this decade."
September 13
CSL (CSLLY) and Arcturus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare, or MHLW, granted approval and authorization for their updated self-amplifying mRNA COVID-19 vaccine, Kostaive. The updated vaccine is targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older. CSL's exclusive partner in Japan, Meiji Seika Pharma, will begin distributing the updated vaccine in time for the October COVID-19 vaccination campaign, marking the world's first commercially available sa-mRNA COVID-19 vaccine for adults 18 and older. In May, a Japanese health ministry panel recommended that COVID-19 vaccines be updated to target the JN.1 lineage of Omicron subvariants for the 2024/2025 national immunization program. This aligns with recent recommendations from the World Health Organization.
Hear more from InvestingChannel by signing up for The Spill.
About "Biotech Alert"
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel's online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
